Barber J M, Boyle D M, Chaturvedi N C, Singh N, Walsh M J
Acta Med Scand Suppl. 1976;587:213-9. doi: 10.1111/j.0954-6820.1976.tb05884.x.
A double blind trial of practolol in coronary heart disease has been conducted for 2 years. In 298 patients with acute myocardial infarction there was no reduction in overall mortality. In a group with initial heart rate over 100 per minute mortality was significantly lowered up to 1 year. Of 484 patients with coronary heart disease treatment for 2 years did not produce a significant reduction in infarction or sudden death. Beta-adrenergic blocking drugs have been shown to reduce left ventricular work and to have an antiarrhythmic action. On these grounds they would seem theoretically to have a place in the management of acute myocardial infarction. Practolol is a cardio-selective beta-blocking agent with an intrinsic sympathomimetic action, but devoid of local anaesthetic effect. It has been found effective in post infarction arrhythmias (1). In early infarction it reduces the area of necrosis as measured by surface ST segment mapping (2).
对心得宁治疗冠心病进行了为期两年的双盲试验。在298例急性心肌梗死患者中，总体死亡率没有降低。在初始心率每分钟超过100次的一组患者中，直至1年时死亡率显著降低。在484例冠心病患者中，治疗2年并未使梗死或猝死显著减少。β-肾上腺素能阻断药已显示可减少左心室作功并具有抗心律失常作用。基于这些理由，它们在理论上似乎在急性心肌梗死的治疗中占有一席之地。心得宁是一种具有内在拟交感神经活性的心脏选择性β受体阻断剂，但无局部麻醉作用。已发现它对梗死后心律失常有效（1）。在梗死早期，通过体表ST段标测测量，它可减少坏死面积（2）。
